Table 1.
Effects of sirtuins on cancer drug resistance
| Types of sirtuin | Types of cancer | Drug | Effect of cancer drug resistance | Year of publication | Ref |
|---|---|---|---|---|---|
| SIRT1 | CRC | TRAIL | miR-128 suppressed SIRT1 expression to sensitize TRAIL-induced apoptosis | 2018 | 177 |
| SIRT1 | Breast cancer | Paclitaxel | A SIRT1-PRRX1-KLF4-ALDH1 circuitry regulates breast cancer stemness and metastasis. KLF4 inhibitor Kenpaullone sensitizes breast cancer cells | 2018 | 178 |
| SIRT1 | Cervical cancer | Paclitaxel | Knockdown of SIRT1 promotes apoptosis of paclitaxel-resistant human cervical cancer cells | 2018 | 179 |
| SIRT1 | ATC | Doxorubicin | 6-phosphogluconate dehydrogenase (6PGD) was critically involved in ATC resistance to doxorubicin. Decreased enzymatic activity of SIRT1 in response to 6PGD inhibition in doxorubicin-resistant ATC cells | 2018 | 180 |
| SIRT1 | Cervical cancer | Doxorubicin | β2-AR activation induces chemoresistance by modulating p53 acetylation through upregulating Sirt1 in cervical cancer cells | 2017 | 181 |
| SIRT1 | Gastric cancer | Cisplatin | miR-132 regulated SIRT1/CREB/ABCG2 signaling pathway contributes to cisplatin resistance | 2017 | 182 |
| SIRT1 | HCC | Oxaliplatin | LncRNA HULC triggered autophagy by stabilizing SIRT1 and attenuates chemosensitivity of HCC cells | 2017 | 183 |
| SIRT1/SIRT3 | Breast and Cervical cancer | Etoposide | Cancer cells with low SIRT1 levels maintained their resistance and survival by increasing SIRT3 expression | 2017 | 148 |
| SIRT1 | Prostate cancer | Docetaxel | The UCA1-miR-204-SIRT1 axis modulates docetaxel sensitivity of prostate cancer cells | 2016 | 184 |
| SIRT1 | Breast cancer | Tamoxifen | Brachyury mediates tamoxifen resistance by regulating SIRT1 | 2016 | 185 |
| SIRT1 | Bladder cancer | Capsaicin | Capsaicin inhibited multiple bladder cancer cells by inhibiting tumor-associated NADH oxidase (tNOX) and SIRT1 | 2016 | 186 |
| SIRT1 | ATL | Etoposide | SIRT1 inhibition enhances chemosensitivity and survival of ATL cells by reducing DNA double-strand repair | 2015 | 187 |
| SIRT1 | Endometrial carcinoma | Cisplatin and paclitaxel | SIRT1 overexpression significantly enhanced drug resistance. Selective SIRT1 inhibitor (EX527) significantly increased chemosensitivity | 2015 | 188 |
| SIRT1 | CML | Hsp90 inhibitors (17-AAG and AUY922) | SIRT1 inhibitors (amurensin G and EX527) effectively potentiated sensitivity of Hsp90 inhibitors | 2015 | 189 |
| SIRT1 | ESCC | Cisplatin | Overexpression of SIRT1 may cause resistance of ESCC cells to cisplatin through Noxa expression | 2015 | 190 |
| SIRT1 | PC | 5-fluorouracil (5-FU) and gemcitabine | Overexpression of miR-494 inhibited chemoresistance of PC by downregulating SIRT1 and c-Myc | 2015 | 191 |
| SIRT1 | CRC | 5-FU | SIRT1/PGC1α-dependent increase in oxidative phosphorylation leads to CRC drug resistance | 2015 | 192 |
| SIRT1 | CML | Imatinib | Divalproex sodium enhances antileukemic effects of imatinib in CML through SIRT1 | 2015 | 193 |
| SIRT1 | AML | TKI (Quizartinib, AC220) | Inhibition of SIRT1 by SIRT1 inhibitor Tenovin-6 (TV6) enhanced TKI-mediated sensitivity | 2014 | 194 |
| SIRT1 | Thyroid cancer | Etoposide | SIRT1-Foxp3 signaling confers drug resistance | 2014 | 195 |
| SIRT1 | Breast cancer | TRAIL | Metformin mediates miR-34a to suppress the SIRT1/PGC-1α/NRF2 pathway and increases drug sensitivity | 2014 | 196 |
| SIRT1 | CML | TKIs (imatinib, nilotinib or dasatinib) | All-trans-retinoic acid (ATRA) effectively blocked acquisition of BCR-ABL mutations and resistance. ATRA inhibited NAD+-dependent SIRT1 deacetylase via CD38 expression | 2014 | 197 |
| SIRT2 | RCC | 5-FU | SIRT2+ cells mediates RCC drug resistance | 2018 | 198 |
| SIRT2 | AML | Daunorubicin, arabinocytidine | SIRT2 mediates multidrug resistance in AML cells via ERK1/2 signaling pathway | 2016 | 199 |
| SIRT2 | Melanoma | Doxorubicin | AC-93253, a SIRT2 inhibitor increases drug sensitivity | 2015 | 200 |
| SIRT3 | Synovial sarcoma | Pazopanib | Knockdown of SIRT3 confers increased resistance to chemotherapeutic agents | 2018 | 201 |
| SIRT3 | HCC | Sorafenib | SIRT3 protein expression was significantly higher in patients treated with metformin | 2017 | 202 |
| SIRT3 | Glioma | Linalool | Overexpression of SIRT3 significantly inhibited a linalool-induced increase of mitochondrial ROS production and apoptotic cell death | 2017 | 203 |
| SIRT3 | Breast cancer | Cisplatin | SIRT3 silencing sensitizes breast cancer cells to cytotoxic treatments through ROS production | 2017 | 124 |
| SIRT4 | CRC | 5-FU | SIRT4 increased the sensitivity of CRC cells to 5-FU | 2016 | 204 |
| SIRT5 | NSCLC | CDDP, 5-FU or bleomycin | SIRT5 facilitates cancer cell growth and drug resistance in NSCLC cells | 2014 | 127 |
| SIRT6 | HCC | Doxorubicin | SIRT6 increased doxorubicin resistance via FOXO3 activity | 2018 | 205 |
| SIRT6 | NSCLC | Gefitinib | Astragaloside IV sensitizes NSCLC cells to gefitinib potentially via regulation of SIRT6 | 2017 | 206 |
| SIRT6 | PC | Gemcitabine | Quinazolinedione SIRT6 inhibitors sensitize cancer treatment | 2015 | 207 |
| SIRT6 | NSCLC | Paclitaxel | SIRT6 knockdown NSCLC cells improved drug sensitivity | 2015 | 120 |
| SIRT6 | Breast cancer | Trastuzumab (Herceptin) | MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes drug resistance | 2014 | 208 |
| SIRT7 | NSCLC | Gemcitabine | Depletion of SIRT7 promoted drug sensitivity | 2018 | 151 |
| SIRT7 | Breast cancer, osteosarcoma, and ovarian cancer | Cisplatin, Doxorubicin | SIRT7 inhibition significantly increases stress resistance and modulates insulin/IGF-1 signaling pathways | 2014 | 209 |
CRC, Colorectal cancer; ATC, Anaplastic thyroid carcinoma; HCC, Hepatocellular carcinoma; ATL, Adult T-cell leukemia-lymphoma; CML, Chronic myeloid leukemia; ESCC, Esophageal squamous cell carcinoma; PC, Pancreatic cancer; AML, Acute myeloid leukemia; RCC, Renal cell carcinoma; and NSCLC, Non-small-cell lung carcinoma.